3RD FLOOR, ALTRINCHAM, CHESHIRE, X0
Centessa Pharmaceuticals Terminates Loan Agreement in Acquisition Process
Material disclosure
Other Events
Annual Report to Security Holders
Ex-99.1
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Amended material disclosure
Announces CEO Transition as Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Q1
FY 2025
Q3
Q2
FY 2024
Amended Quarterly Report
Notice of Suspension of Duty to File Reports
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Merger Proxy Statement
Definitive Proxy Statement
Additional Proxy Materials
Definitive Additional Information Statement
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Automatic Shelf Registration Statement
S-8 POS
PREM14A